Gramicidin A induces metabolic dysfunction and energy depletion leading to cell death in renal cell carcinoma cells

Molecular Cancer Therapeutics

Volumn 12, Issue 11, 2013, Pages 2296-2307

  David, Justin M ^a,b   Owens, Tori A ^b   Barwe, Sonali P ^b   Rajasekaran, Ayyappan K ^b  

^a UNIVERSITY OF DELAWARE   (United States)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRAMICIDIN A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MONENSIN; VON HIPPEL LINDAU PROTEIN;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOMA CELL; CELL ASSAY; CELL ENERGY; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFECT; GLYCOLYSIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL DEATH; CELL LINE, TUMOR; DOGS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GLYCOLYSIS; GRAMICIDIN; HEK293 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; MADIN DARBY CANINE KIDNEY CELLS; MALE; MICE; MICE, NUDE; OXIDATIVE PHOSPHORYLATION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887486981     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Kevin DA II, Meujo DAF, Hamann MT. Polyether ionophores: broadspectrum and promising biologically active molecules for the control of drug-resistant bacteria and parasites. Expert Opin Drug Discov 2009;4:109-46.
2. Park WH, Jung CW, Park JO, Kim K, Kim WS, Im YH, et al. Monensin inhibits the growth of renal cell carcinoma cells via cell cycle arrest or apoptosis. Int J Oncol 2003;22:855-60.
3. Park WH, Kim ES, Jung CW, Kim BK, Lee YY. Monensin-mediated growth inhibition of SNU-C1 colon cancer cells via cell cycle arrest and apoptosis. Int J Cancer 2003;22:377-82.
4. Park WH, Kim ES, Kim BK, Lee YY. Monensin-mediated growth inhibition in NCI-H929 myeloma cells via cell cycle arrest and apoptosis. Int J Oncol 2003;23:197-204.
5. Park WH, Lee MS, Park K, Kim ES, Kim BK, Lee YY. Monensinmediated growth inhibition in acute myelogenous leukemia cells via cell cycle arrest and apoptosis. Int J Cancer 2002;101: 235-42.
6. Park WH, Seol JG, Kim ES, Kang WK, Im YH, Jung CW, et al. Monensin-mediated growth inhibition in human lymphoma cells through cell cycle arrest and apoptosis. Br J Haematol 2002; 119:400-7.
7. Ketola K, Vainio P, Fey V, Kallioniemi O, Iljin K. Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells. Mol Cancer Ther 2010;9: 3175-85.
8. He Z, Zhang Y, Mehta SK, Pierson DL, Wu H, Rohde LH. Expression profile of apoptosis related genes and radio-sensitivity of prostate cancer cells. J Radiat Res 2011;52:743-51.
9. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, et al. Identification of selective inhibitors of cancer stem cells by highthroughput screening. Cell 2009;138:645-59.
10. Naujokat C, Steinhart R. Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol 2012;2012:950658.
11. Dubos RJ. Studies on a bactericidal agent extracted from a soil Bacillus: I. Preparation of the agent. its activity in vitro. J Exp Med 1939;70:1-10.
12. Dubos RJ, Hotchkiss RD. The production of bactericidal substances by aerobic sporulating bacilli. J Exp Med 1941;73:629-40.
13. Kelkar DA, Chattopadhyay A. The gramicidin ion channel: a model membrane protein. Biochim Biophys Acta 2007;1768:2011-25.
14. Wang F, Qin L, Pace CJ, Wong P, Malonis R, Gao J. Solubilized gramicidin A as potential systemic antibiotics. Chembiochem 2012; 13:51-5.
15. Otten-Kuipers MA, Beumer TL, Kronenburg NA, Roelofsen B, Op den Kamp JA. Effects of gramicidin and tryptophan-N-formylated gramicidin on the sodium and potassium content of human erythrocytes. Mol Membr Biol 1996;13:225-32.
16. Bourinbaiar AS, Coleman CF. The effect of gramicidin, a topical contraceptive and antimicrobial agent with anti-HIV activity, against herpes simplex viruses type 1 and 2 in vitro. Arch Virol 1997; 142:2225-35.
17. Moll GN, van den Eertwegh V, Tournois H, Roelofsen B, Op den Kamp JA, van Deenen LL. Growth inhibition of Plasmodium falciparum in in vitro cultures by selective action of tryptophan-N-formylated gramicidin incorporated in lipid vesicles. Biochim Biophys Acta 1991;1062: 206-10.
18. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
19. Baldewijns MM, van Vlodrop IJ, Schouten LJ, Soetekouw PM, de Bruine AP, van Engeland M. Genetics and epigenetics of renal cell cancer. Biochim Biophys Acta 2008;1785:133-55.
20. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005;23: 2763-71.
21. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010;29:625-34.
22. Shen C, Kaelin WG Jr. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol 2013;23:18-25.
23. Haase VH. Renal cancer: oxygen meets metabolism. Exp Cell Res 2012;318:1057-67.
24. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006;12: 122-7.
25. Gorospe M, Egan JM, Zbar B, Lerman M, Geil L, Kuzmin I, et al. Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells. Mol Cell Biol 1999;19: 1289-300.
26. Kondo K, Klco J, Nakamura E, Lechpammer M, KaelinWGJr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002;1:237-46.
27. Yan Q, Bartz S, Mao M, Li L, Kaelin WG Jr. The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo. Mol Cell Biol 2007;27:2092-102.
28. Suwaki N, Vanhecke E, Atkins KM, Graf M, Swabey K, Huang P, et al. A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Sci Transl Med 2011;3:85ra47.
29. + pump in quiescent fibroblasts by increasing Na+ entry. Proc Natl Acad Sci U S A 1978;75:5560-4.
30. Zong WX, Thompson CB. Necrotic death as a cell fate. Genes Dev 2006;20:1-15.
31. Woodard J, Joshi S, Viollet B, Hay N, Platanias LC. AMPK as a therapeutic target in renal cell carcinoma. Cancer Biol Ther 2010;10: 1168-77.
32. Skou JC. The influence of some cations on an adenosine triphosphatase from peripheral nerves. Biochim Biophys Acta 1957;23: 394-401.
33. Rajasekaran SA, Beyenbach KW, Rajasekaran AK. Interactions of tight junctions with membrane channels and transporters. Biochim Biophys Acta 2008;1778:757-69.
34. Sorochkina AI, Plotnikov EY, Rokitskaya TI, Kovalchuk SI, Kotova EA, Sychev SV, et al. N-terminally glutamate-substituted analogue of gramicidin A as protonophore and selective mitochondrial uncoupler. PLoS ONE 2012;7:e41919.
35. Emaus RK, Grunwald R, Lemasters JJ. Rhodamine 123 as a probe of transmembrane potential in isolated rat-liver mitochondria: spectral and metabolic properties. Biochim Biophys Acta 1986;850: 436-48.
36. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005;1:112-9.
37. Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel L, et al. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 2009;14:364-75.
38. Ewald G, Sundin P. ATP leakage from ELD cells after exposure to stearic, monochlorostearic, dichlorostearic, and oleic acids. Pharmacol Toxicol 1993;73:159-62.
39. Clausen T, Van Hardeveld C, Everts ME. Significance of cation transport in control of energy metabolism and thermogenesis. Physiol Rev 1991;71:733-74.
40. Hao W, Chang CP, Tsao CC, Xu J. Oligomycin-induced bioenergetic adaptation in cancer cells with heterogeneous bioenergetic organization. J Biol Chem 2010;285:12647-54.
41. Grayson ML, Kucers A. Kucers' the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs. 6th ed. London: Hodder Arnold; 2010.
42. Goldberg EP, Hadba AR, Almond BA, Marotta JS. Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery. J Pharm Pharmacol 2002;54:159-80.
43. Krishnan V, Xu X, Barwe SP, Yang X, Czymmek K, Waldman SA, et al. Dexamethasone-loaded block copolymer nanoparticles induce leukemia cell death and enhance therapeutic efficacy: a novel application in pediatric nanomedicine. Mol Pharm 2013;10:2199-210.